GlassScriptPhysician profile
James R Pearson
NPI 1598756942
$11,788.94
in general payments reported to CMS, 2019-2025
43 companies · $2,728 in 2025
The $2,728 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,092 · 2022: $1,682 · 2023: $2,353 · 2024: $2,934 · 2025: $2,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,830 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,830.26 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,415.97 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $920.05 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $903.55 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Novo Nordisk INC | $789.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $701.91 | 2021-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $638.55 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Daiichi Sankyo INC. | $437.93 | 2023-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $431.18 | 2021-2025 | |
| Astellas Pharma US INC | $417.30 | 2022-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $395.22 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $374.83 | 2021-2025 | |
| Corcept Therapeutics | $238.66 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $236.29 | 2022-2024 | Quviviq |
| Abbott Laboratories | $176.61 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $175.00 | 2021-2025 | Repatha, Otezla, Repatha |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $163.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $147.55 | 2022 | |
| Vanda Pharmaceuticals INC. | $145.15 | 2024-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $124.54 | 2021 | |
| Almatica Pharma LLC | $78.68 | 2021 | |
| Scilex Pharmaceuticals INC. | $66.23 | 2023-2025 | Ztlido |
| Mylan Specialty L.P. | $65.54 | 2022-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $62.71 | 2024-2025 | Rexulti |
| Insulet Corporation | $58.85 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.53 | 2025 | Caplyta |
| Soleno Therapeutics, INC. | $52.22 | 2025 | Vykat Xr |
| Merck Sharp & Dohme LLC | $51.06 | 2021-2022 | |
| Lundbeck LLC | $47.39 | 2023-2025 | Vyepti, Rexulti |
| Xeris Pharmaceuticals, INC. | $41.09 | 2023-2024 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $40.87 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $38.80 | 2023 | Senza |
| Dexcom, INC. | $38.79 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $35.41 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.57 | 2021 | |
| Indivior INC. | $28.54 | 2024 | Sublocade |
| Aimmune Therapeutics, INC. | $25.85 | 2025 | Zenpep |
| Phadia US INC. | $25.78 | 2023 | Immunocap |
| Neurocrine Biosciences, INC. | $22.94 | 2024 | Ingrezza |
| Viatris Specialty LLC | $20.51 | 2025 | Yupelri |
| Tanabe Pharma America, INC. | $20.12 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.39 | 2022 | |
| Medtronic, INC. | $16.75 | 2021 | |
| Philips North America LLC | $15.57 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.